Arkadios Wealth Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-38,735
Closed -$2.89M 648
2021
Q3
$2.89M Sell
38,735
-18,579
-32% -$1.56M 0.42% 57
2021
Q2
$5.3M Sell
57,314
-14,039
-20% -$1.19M 0.65% 21
2021
Q1
$6.33M Buy
71,353
+3,162
+5% +$314K 1.04% 12
2020
Q4
$6.36M Buy
+68,191
New +$5.43M 1.33% 8

Other funds holding ARKG

Arkadios Wealth Advisors's ARKG Position: Q4 2021 in Review

Arkadios Wealth Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2021, closing a stake of 38,735 shares — an estimated $2.89M sold.

Arkadios Wealth Advisors first reported a position in ARKG in Q4 2020 and held it in 4 quarters. The position peaked at $6.36M in Q4 2020. 460 funds tracked by Wall St. Rank hold ARKG as of Q4 2021.

  • Arkadios Wealth Advisors reported no remaining ARK Genomic Revolution ETF position as of Q4 2021 after selling out during the quarter.
  • Arkadios Wealth Advisors sold 38,735 ARK Genomic Revolution ETF shares in Q4 2021, an estimated $2.89M.
  • Arkadios Wealth Advisors first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 4 quarters.
  • Arkadios Wealth Advisors's ARK Genomic Revolution ETF position peaked at $6.36M in Q4 2020.
  • 460 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2021.

Based on Arkadios Wealth Advisors's 13F filing for Q4 2021, filed 3 Feb 2022.